Quality of life with first-line ribociclib plus endocrine therapy vs combination chemotherapy in clinically aggressive HR+/HER2− ABC: RIGHT Choice
Year: 2026
Type: article
Abstract: BACKGROUND: The RIGHT Choice phase 2 randomized clinical trial of pre/perimenopausal women with clinically aggressive hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (ABC) reported a statistically significant progression-free survival benefit with ribociclib plus endocrine therapy (ET) over combination chemotherapy (21.8 vs 12.8 months; HR, 0.61; 95% CI: 0.43-0.87; P = .003), with lower rates of symptomatic adverse events. This prespecified analysis compared QOL outcomes between treatment arms in RIGHT Choice to support treatment decision-making in these patients. PATIENTS AND METHODS: Pre/perimenopausal women with clinically aggressive HR+/HER2- ABC were randomized 1:1 to first-line ribociclib plus letrozole/anastrozole/goserelin or investigator's choice of combination chemotherapy. Median time to definitive deterioration (mTTDD) from randomization in Functional Assessment of Cancer Therapy-Breast (FACT-B) scores (≥10%) or a composite mTTDD endpoint (including treatment discontinuation) was determined by Kaplan-Meier methods. RESULTS: mTTDD in FACT-B overall health status, trial outcome index (TOI), and nausea scores was prolonged in patients receiving ribociclib plus ET versus combination chemotherapy (HR, 0.72, 0.63, and 0.59, respectively), while the pain score was similar between treatment arms (HR, 1.05). The composite mTTDD in overall health status, TOI, pain, and nausea scores was longer in patients in the ribociclib arm (HR, 0.68, 0.65, 0.76, and 0.62, respectively). CONCLUSIONS: Treatment with first-line ribociclib plus ET translates into improved QOL versus combination chemotherapy in patients with clinically aggressive HR+/HER2- ABC. These data reinforce efficacy and safety findings supporting cyclin-dependent kinase 4 and 6 inhibitors plus ET as the preferred option in this population. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, NCT03839823.
Source: The Oncologist
Institutions: American University of Beirut Medical Center, King Hussein Cancer Center, Seoul National University, Seoul National University Hospital, National Taiwan University Hospital, National Cancer Centre Singapore, Cairo University, Phramongkutklao Hospital, Moscow Clinical Scientific Center, Novartis (United States), Novartis (Switzerland), Acıbadem University
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,852
OpenAlex ID: W7236778226
